MX2021010025A - Tratamiento de lesión renal. - Google Patents

Tratamiento de lesión renal.

Info

Publication number
MX2021010025A
MX2021010025A MX2021010025A MX2021010025A MX2021010025A MX 2021010025 A MX2021010025 A MX 2021010025A MX 2021010025 A MX2021010025 A MX 2021010025A MX 2021010025 A MX2021010025 A MX 2021010025A MX 2021010025 A MX2021010025 A MX 2021010025A
Authority
MX
Mexico
Prior art keywords
kidney injury
treatment
methods
agents
treating
Prior art date
Application number
MX2021010025A
Other languages
English (en)
Inventor
Stuart Alexander Cook
Sebastian Schaefer
Anissa Anindya Widjaja
Original Assignee
Singapore Health Serv Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singapore Health Serv Pte Ltd filed Critical Singapore Health Serv Pte Ltd
Publication of MX2021010025A publication Critical patent/MX2021010025A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describen métodos para tratar y prevenir la lesión renal mediante la inhibición de la señalización mediada por interleucina 11 (IL-11), así como agentes para su uso en dichos métodos.
MX2021010025A 2019-02-22 2020-02-21 Tratamiento de lesión renal. MX2021010025A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1902419.9A GB201902419D0 (en) 2019-02-22 2019-02-22 Treatment of kidney injury
PCT/EP2020/054580 WO2020169783A1 (en) 2019-02-22 2020-02-21 Treatment of kidney injury

Publications (1)

Publication Number Publication Date
MX2021010025A true MX2021010025A (es) 2021-11-12

Family

ID=65998854

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010025A MX2021010025A (es) 2019-02-22 2020-02-21 Tratamiento de lesión renal.

Country Status (14)

Country Link
US (2) US11339216B2 (es)
EP (1) EP3927742A1 (es)
JP (1) JP2022521591A (es)
KR (1) KR20210144708A (es)
CN (1) CN113748131A (es)
AU (1) AU2020224346A1 (es)
BR (1) BR112021016613A2 (es)
CA (1) CA3130027A1 (es)
CL (1) CL2021002212A1 (es)
EA (1) EA202191988A1 (es)
GB (1) GB201902419D0 (es)
MX (1) MX2021010025A (es)
TW (1) TW202037605A (es)
WO (1) WO2020169783A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022122010A1 (zh) * 2020-12-11 2022-06-16 江苏恒瑞医药股份有限公司 Jak抑制剂在肾脏疾病中的应用
WO2023023473A1 (en) * 2021-08-16 2023-02-23 Sierra Oncology, Inc. Methods of using momelotinib to treat chronic kidney disease
CN115068442A (zh) * 2021-09-13 2022-09-20 荣灿生物医药技术(上海)有限公司 核酸的纳米颗粒组合物、其制备方法和用途
CN113960302B (zh) * 2021-09-29 2024-04-23 中国人民解放军军事科学院军事医学研究院 一种基于高内涵技术的肾毒性检测方法及其应用
WO2023111196A1 (en) * 2021-12-16 2023-06-22 Singapore Health Services Pte. Ltd. Treatment and prevention of glomerular disease
CN114982708A (zh) * 2022-05-11 2022-09-02 成都医学院第一附属医院 一种小鼠造影剂肾病模型及其构建方法
GB202218388D0 (en) 2022-12-07 2023-01-18 Vvb Bio Pte Ltd GP130 antigen-binding molecules

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
ES2093562B1 (es) 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US6649192B2 (en) 1996-07-29 2003-11-18 Universidade De Santiago De Compostela Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
AU1086501A (en) 1999-10-15 2001-04-30 Carnegie Institution Of Washington Rna interference pathway genes as tools for targeted genetic interference
KR101704953B1 (ko) * 2006-07-05 2017-02-08 피브로테크 세라퓨틱 피티와이 엘티디 치료 화합물
EP2215113B1 (en) 2007-10-26 2015-02-25 CSL Limited Cytokine muteins
US8182814B2 (en) 2007-10-26 2012-05-22 Csl Limited Methods of treating inflammatory airway conditions by inhibition of IL-11 activity
US8518888B2 (en) 2008-10-14 2013-08-27 Csl Limited Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
JP6545105B2 (ja) 2013-02-07 2019-07-17 シーエスエル、リミテッド Ｉｌ−１１ｒ結合タンパク質及びその使用
GB201522186D0 (en) * 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
CN108210909A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗脂质肾损伤的药物及其用途
CN108210908A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗药物性肾损伤的药物及其用途
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
GB201621431D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore The Decoy cytokine receptor
CA3045871A1 (en) 2016-12-16 2018-06-21 Singapore Health Services Pte Ltd Il-11 antibodies
GB201716733D0 (en) 2017-10-12 2017-11-29 Nat Univ Singapore Treatment of SMC mediated disease
GB201806918D0 (en) 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
GB201809699D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201809700D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies

Also Published As

Publication number Publication date
TW202037605A (zh) 2020-10-16
KR20210144708A (ko) 2021-11-30
CN113748131A (zh) 2021-12-03
GB201902419D0 (en) 2019-04-10
EA202191988A1 (ru) 2021-12-08
WO2020169783A1 (en) 2020-08-27
BR112021016613A2 (pt) 2021-11-03
EP3927742A1 (en) 2021-12-29
AU2020224346A1 (en) 2021-10-07
CA3130027A1 (en) 2020-08-27
JP2022521591A (ja) 2022-04-11
CL2021002212A1 (es) 2022-04-18
US20220403017A1 (en) 2022-12-22
US20200270340A1 (en) 2020-08-27
US11339216B2 (en) 2022-05-24

Similar Documents

Publication Publication Date Title
MX2021010025A (es) Tratamiento de lesión renal.
MX2021008727A (es) Tratamiento de la hepatotoxicidad.
MX2020001732A (es) Tratamiento de las afecciones del sistema nervioso central.
PH12020551923A1 (en) Methods and compositions for treating cancer
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
MD3464271T2 (ro) Derivați de pirazol în calitate de inhibitori ai kaliсreinei plasmatice
MX2021013356A (es) Tratamiento y prevencion de enfermedades metabolicas.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
MX2019010040A (es) Composiciones y métodos para el tratamiento del cáncer.
MX2018014577A (es) Combinacion de anticuerpo anti-cd20, inhibidor selectivo de quinasa p13-delta, e inhibidor de btk para tratar trastornos proliferativos de celulas b.
MX2022001004A (es) Inhibidores de enzimas.
GB201014026D0 (en) Treatment
MX2020006297A (es) Variantes de cd19.
MX2021004598A (es) Inhibidores selectivos de rgmc y el uso de los mismos.
MX2022007285A (es) Compuestos, polimeros, dispositivos y usos de los mismos.
MX2022002069A (es) Inhibidores de enzimas.
MX2021004709A (es) Metodo y medicamento para tratar cancer insensible a inhibidor de se?alizacion de pd-1/pd-l1.
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
MX2018013507A (es) Composiciones y metodos para el tratamiento de la inflamacion o infeccion del ojo.
ZA202106519B (en) Caspase inhibitors and methods of use thereof
MX2022011564A (es) Tratamiento del dolor.
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MX2022005250A (es) Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b.
PH12019502578A1 (en) Methods of treatment for cervical dystonia